Figure 6.

NU2058 suppresses CRC tumor growth in orthotopic xenograft models and PDX models and enhances sensitivity to SN38 and oxaliplatin. A) DLD1 and HCT15 cells were injected below the cecum to establish orthotopic xenograft models in nude mice, and the mice were given NU2058 (15 mg kg⁻¹) or DMSO every 5 days (n = 5). B) Representative images and quantification of tumor nodules. C) Hematoxylin–eosin staining of mouse intestines. D) Schematic diagram showing the approach to establish patient‐derived xenografts (PDXs). E) Representative images and growth curves showing the growth of PDX tumors upon NU2058 treatment (n = 5). F) Immunohistochemical analysis of Ki‐67 in NU2058‐treated PDX tumors (n = 3). G) Western blotting was used to detect the expression of cyclin D1, CDK4, c‐Myc, and lamin B1 in PDX tumors. H,I) WST‐1 and colony formation assays suggested that NU2058 enhances the sensitivity of CRC cells to SN38 and oxaliplatin. Bars, SD; *p < 0.05; **p < 0.01; ***p < 0.001.